SecBot SecBot
SECBOTREPLAY Home › Report › SRXH

SRXH · SRX Global Inc

SRX Global Inc · PRESS-RELEASE filed Aug 4, 2026 at 05:00 ET

At the news

BULLISHIMPACT 6/10

PRESS-RELEASE filed Aug 4, 2026 at 05:00 ET

SRX Global Inc. (SRXH) announced it has acquired a stake in Vistagen Therapeutics (VTGN), a late clinical-stage biopharma company. SRX views VTGN shares as undervalued and signaled openness to constructive engagement with Vistagen's leadership to discuss unlocking shareholder value. This is a small-cap activist-style investment by SRX, not a full acquisition, and the stake size and price were not disclosed.

  • SRX Global acquired a stake in Vistagen Therapeutics (VTGN), a late clinical-stage biopharma company.
  • SRX views VTGN shares as undervalued and welcomes constructive engagement with Vistagen's leadership and Board.
  • The size of the stake, purchase price, and percentage ownership were not disclosed.
  • SRX describes itself as an AI-enabled platform investing in high-conviction operating companies and strategic assets.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access